ADHANSIA XR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Adhansia Xr, and what generic alternatives are available?
Adhansia Xr is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are twelve patents protecting this drug.
This drug has thirty-three patent family members in seventeen countries.
The generic ingredient in ADHANSIA XR is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adhansia Xr
A generic version of ADHANSIA XR was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ADHANSIA XR?
- What are the global sales for ADHANSIA XR?
- What is Average Wholesale Price for ADHANSIA XR?
Summary for ADHANSIA XR
International Patents: | 33 |
US Patents: | 12 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 84 |
Clinical Trials: | 2 |
Patent Applications: | 3,544 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ADHANSIA XR |
What excipients (inactive ingredients) are in ADHANSIA XR? | ADHANSIA XR excipients list |
DailyMed Link: | ADHANSIA XR at DailyMed |
![ADHANSIA XR drug patent expirations Drug patent expirations by year for ADHANSIA XR](/p/graph/s/t/ADHANSIA_XR-patent-expirations.png)
![Drug Prices for ADHANSIA XR](/p/graph/drug-price/ADHANSIA+XR.png)
Recent Clinical Trials for ADHANSIA XR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Purdue Pharma LP | Phase 4 |
US Patents and Regulatory Information for ADHANSIA XR
ADHANSIA XR is protected by twelve US patents and one FDA Regulatory Exclusivity.
Patents protecting ADHANSIA XR
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting ADHANSIA XR
LABELING REVISIONS RELATED TO CLINICAL STUDIES
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-006 | Feb 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-004 | Feb 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-003 | Feb 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-004 | Feb 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-005 | Feb 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ADHANSIA XR
See the table below for patents covering ADHANSIA XR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2015337779 | Methods and compositions particularly for treatment of attention deficit disorder | ⤷ Sign Up |
South Korea | 20170115036 | 특히 주의력 결핍 장애의 치료를 위한 방법 및 조성물 (METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER) | ⤷ Sign Up |
South Korea | 102487506 | ⤷ Sign Up | |
Canada | 3018328 | METHODES ET COMPOSITIONS DESTINEES AU TRAITEMENT DU TROUBLE DE DEFICIT D'ATTENTION (METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER) | ⤷ Sign Up |
Brazil | 112017008993 | métodos e composições especificamente para o tratamento de transtorno de déficit de atenção | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |